Hints and tips:
Related Special Reports
...Seventy per cent of healthcare companies expect M&A activity in healthcare to increase in 2024 after two relatively quiet years, according to a recent global survey from Jefferies....
...The US healthcare system is separated into hundreds of for-profit companies that are under increasing pressure to cut costs, which has spurred consolidation in the sector....
...In contrast, defensive sectors that provide shelter in a downturn (healthcare, utilities, staples) have all underperformed the index in recent months....
...Cigna is reportedly in talks to merge with Humana in a deal that would create a US health insurance company worth $140bn....
...Johnson & Johnson has struck a deal to buy medical device maker Shockwave Medical for $13.1bn, as the healthcare giant puts cash to work from the spin-off of its consumer health arm to pursue acquisitions...
...It recently hired Wentworth, a former Cigna executive, as part of its plans to develop its healthcare services....
...He noted that “nation state actors” and “ransomware teams” were “locking in” on healthcare and other infrastructure. A cynic might argue that such warnings are not new....
...It’s a good growth business because basically healthcare prices go up and health insurance premiums are, you know, grow with healthcare costs. And Cigna is the cheapest of the group....
...One consequence, after successive rounds of consolidation, is a mooted $140bn insurance tie-up between Cigna and Humana....
...An all-day/half-day session on AI in healthcare....
...That designation would give them access to benefits, such as social security and healthcare. The onus now will be on companies to prove that their workers are not employees....
...Much the same is now happening on a broader front as mobile computing invades markets including healthcare, where medical device companies have their own IP moats....
...This is the last mile of healthcare. Some big regulatory issues too of course. WhatsApp to WesPete: Ha, no I wouldn’t call myself a futurist. Just a comms guy with an eye on the horizon....
...Antitrust regulators are really going after high-profile transactions and deals in the healthcare sector. Cigna and Humana have tried other mergers in the past few years. Both of them were struck down....
...Fundraising volumes have risen, with about $3.5bn raised compared to just $500mn in the same period in 2023, according to Dealogic, but the two largest deals — sportswear maker Amer Sports and healthcare...
...Ansys, which has headquarters in Pennsylvania and has its origins in structural analysis tools, makes engineering simulation software used in industries from automotive and construction to healthcare and...
...One thing to start: Cigna is in talks to merge with Humana in a deal that would create a US health insurance giant worth $140bn and provide a significant test for antitrust authorities, according to people...
...Healthcare payments software group Waystar filed publicly for an IPO in November, but ultimately held back....
...“A lot of people saw the telemedicine component as an antidote to WeightWatchers’ foes, but I saw a very competitive market that they were entering,” said Stephanie Davis, a healthcare technology analyst...
...US health insurer Cigna has abandoned plans to merge with Humana, a blockbuster transaction that would have created a $140bn insurance giant, according to people familiar with the matter....
...It culminated last week with the sale of a $5bn loan that backed KKR’s purchase of a stake in a healthcare technology company known as Cotiviti....
...Humana shed more than 12 per cent, CVS Health dropped 6 per cent and Cigna fell 4 per cent....
...With premiums still rolling in, the country’s leading health insurers — UnitedHealth, Cigna, Elevance Health (formerly known as Anthem) and Humana — raked in record revenues and robust profits in each of...
...Veritas Capital is in talks to sell a 50 per cent stake in healthcare technology company Cotiviti to private equity giant KKR, in a deal that would value the business at up to $11bn, according to three people...
...The Medicines and Healthcare products Regulatory Agency has approved the therapy, called Casgevy, which was developed by Vertex Pharmaceuticals and Crispr Therapeutics....
International Edition